<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01612286</url>
  </required_header>
  <id_info>
    <org_study_id>ZhejaingCH-npc-02</org_study_id>
    <nct_id>NCT01612286</nct_id>
  </id_info>
  <brief_title>Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Phase II Clinical Study of Endostar Combination With Chemotherapy in the Metastatic Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators designed this study to evaluate the efficiency and the acute toxicities of
      recombinant human endostatin (endostar) combined with chemotherapy in the metastatic
      nasopharyngeal carcinoma (NPC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the progression free survival (PFS), overall survival (OS), Acute adverse
      reaction of recombinant human endostatin (endostar) combined with chemotherapy to the
      metastatic nasopharyngeal carcinoma (NPC).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progress free survival(PFS)</measure>
    <time_frame>1 year and 2years</time_frame>
    <description>PFS means assignament to the date of any local or distant progress of the disease useing Kaplan-Meier caculate the progress free survival rates</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival(OS)</measure>
    <time_frame>baseline to date of death from any cause</time_frame>
    <description>the overall survival denote to assignment to date of death from any cause. Using Kaplan-Meier to caculate the 1-year ,2-year,3-year overall survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>participants will be followed for the duration of hospital stay,an expected average of 100 days and every 3 months thereafter for 1 year</time_frame>
    <description>observe and record the toxicity profile(incluing but not limit to mocositis,liver and kidney function,et al.)according NCI-CTCAE(3rd edtion) during the chemotherapy,Targeted therapy and follow-up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>endostatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chemotherapy concurrently with endostatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>endostatin</intervention_name>
    <description>Gemcitabine 1.0g/m2 d1,8 cisplatin 80mg/m2 endostatin 15mg/d 14days/cycle *4cycles</description>
    <arm_group_label>endostatin</arm_group_label>
    <other_name>endostar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed metastatic NPC patient who have received radiotherapy or chemoradiotherapy
             with an at least 6 months interval

          -  Have measurable lesions

          -  No dysfunction of the major organs

          -  Can understand this study and give a signed informed consent certificates

          -  without a history of allergic reaction to the biological agents

        Exclusion Criteria:

          -  Pregnant or lactating women; Women of child-bearing age without contraception

          -  with a Serious infection or dysfunction of the major organs

          -  have taken other antitumor drugs during the period of 30 days ahead of this clinical
             trial

          -  allergic to the Escherichia coli preparations

          -  Cann't understand this study and give a signed informed consent certificates
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bin Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhejiang cancer hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2012</study_first_submitted>
  <study_first_submitted_qc>June 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2012</study_first_posted>
  <last_update_submitted>February 16, 2014</last_update_submitted>
  <last_update_submitted_qc>February 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recombinant human endostatin</keyword>
  <keyword>nasopharyngeal carcinoma</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

